Drugs for chronic obstructive pulmonary disease

Current Medicinal Chemistry

Volumn 20, Issue 12, 2013, Pages 1461-1463

  Montuschi, Paolo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABEDITEROL; ACLIDINIUM BROMIDE; CARMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; MILVETEROL; OGLEMILAST; OLODATEROL; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE; VILANTEROL;

BODY WEIGHT; BRONCHIOLITIS; BRONCHODILATATION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALER; NAUSEA; OXIDATIVE STRESS; PNEUMONIA; SIDE EFFECT;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG DISCOVERY; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84877966510     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320120001     Document Type: Editorial

References (19)

1. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2013). Available at: Www.goldcopd.org.
2. Keating, G. M. Tiotropium bromide inhalation powder: A review of its use in the management of chronic obstructive pulmonary disease. Drugs, 2012, 72, 273-300
3. Dong, Y. H.; Lin, H. H.; Shau, W. Y.; Wu, Y. C.; Chang, C. H.; Lai, M. S. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: Systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax, 2013, 68, 48-56
4. Alagha, K.; Bourdin, A.; Tummino, C.; Chanez, P. An update on the efficacy and safety of aclidinium bromide in patients with COPD. Ther. Adv. Respir. Dis., 2011, 5, 19-28
5. Vogelmeier, C.; Banerji, D. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis., 2011, 5, 163-173
6. McKeage, K. Indacaterol: A review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs, 2012, 72, 543-563
7. van Noord, J. A.; Buhl, R.; Laforce, C.; Martin, C.; Jones, F.; Dolker, M.; Overend, T. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax, 2010, 65, 1086-1091
8. Calverley, P. M. A.; Anderson, J. A.; Celli, B.; Ferguson, G. T.; Jenkins, C.; Jones, P. W.; Yates, J. C.; Vestbo, J. for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New. Eng. J. Med., 2007, 356, 775-789
9. Nannini, L. J.; Lasserson, T. J.; Poole, P. Combined corticosteroid and long-acting-2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev., 2012, 9, CD006829
10. Page, C. P.; Spina, D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr. Opin. Pharmacol., 2012, 12, 275-286
11. Calverley, P. M.; Rabe, K. F.; Goehring, U. M.; Kristiansen, S.; Fabbri, L. M.; Martinez, F. J.; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet, 2009, 374, 685-694
12. Vestbo, J.; Tan, L.; Atkinson, G.; Ward, J.; UK-500,001 Global Study Team. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur. Respir. J., 2009, 33, 1039-1044
13. Fortin, M.; D'Anjou, H.; Higgins, M. E.; Gougeon, J.; Aubé, P.; Moktefi, K.; Mouissi, S.; Séguin, S.; Séguin, R.; Renzi, P. M.; Parquet, L;, Ferrari, N. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. Respir. Res., 2009, 10, 39.
14. Burgin, A. B.; Magnusson, O. T.; Singh, J.; Witte, P.; Staker, B. L.; Bjornsson, J. M.; Thorsteinsdottir, M.; Hrafnsdottir, S.; Hagen, T.; Kiselyov, A. S.; Stewart, L. J.; Gurney, M. E. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat. Biotechnol., 2010, 28, 63-70
15. Milara, J.; Navarro, A.; Almudéver, P.; Lluch, J.; Morbillo, E.J.; Cortijo, J. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin. Exp. Allergy, 2011, 41, 535-546
16. Boswell-Smith, V.; Spina, D.; Oxford, A.W.; Comer, M.B.: Seeds, E.A.; Page, C.P. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl- 2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a] isoquinolin-4-one]. J. Pharmacol. Exp. Ther., 2006, 318, 840-848
17. Gross, N.J. Novel antiinflammatory therapies for COPD. Chest, 2012, 142, 1300-1307
18. Smith, S.J.; Cieslinski, L.B.; Newton, R.; Donnelly, L.E.; Fenwick, P.S.; Nicholson, A.G.; Barnes, P.J.; Barnette, M.S.; Giembycz, M.A. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: In vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol. Pharmacol., 2004, 6, 1679-1689
19. Hughes, A.D.; McNamara, A.; Steinfeld, T. Multivalent dual pharmacology muscarinic antagonist and-2 agonist (MABA) molecules for the treatment of COPD. Prog. Med. Chem., 2012, 51, 71-95